Autres langues Moderna, Inc.

Actions

MRNA

US60770K1079

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 12/06/2026			Varia. 5j.	Varia. 1 janv.
49,91 ^USD	+0,54 %		+5,21 %	+69,24 %

09/06	Transcript : Moderna, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 03:20 PM
09/06	Ebola Bundibugyo : le point sur les vaccins et traitements en cours de développement	RE

Autres langues

11/06	Impfstoffdeals: Gutachten sieht Verstoß der EU-Kommission
09/06	Las vacunas contra el cáncer basadas en ARNm avanzan a pesar de los recortes en EEUU
09/06	What Bundibugyo Ebola vaccines and treatments are under development
09/06	Cancer vaccines based on mRNA advance, despite US cuts
09/06	Moderna, University of Oxford Receive UK Approval to Begin Study of Cancer Vaccine
09/06	Moderna Receives UK Authorization to Evaluate Cancer Vaccine for Lynch Syndrome
09/06	Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
04/06	What Bundibugyo Ebola vaccines and treatments are under development
03/06	HEALTH ROUNDS-Radiation-emitting implant improves outcomes after brain cancer surgery
02/06	Moderna to Present at Upcoming Conference in June 2026
02/06	Drugmaker Moderna, other groups get $60 mln to develop Ebola vaccine
02/06	Noch 7,6 Millionen Dosen Corona-Impfstoff auf Lager
01/06	Jefe de OMS se reúne con presidente del Congo, grupo dice que ébola pudo propagarse por meses sin ser detectado
01/06	WHO chief wraps up visit to Ebola-hit Congo, briefs president on response
01/06	Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
01/06	Moderna entwickelt Impfstoff gegen Ebola-Ausbruch im Kongo
01/06	Moderna Expands Collaboration With CEPI to Develop Bundibugyo Ebolavirus Vaccine
01/06	Moderna and other groups get $60 million to develop Ebola vaccine
01/06	CEPI commits up to $50 million to develop Bundibugyo Ebola vaccine with Moderna
01/06	Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
29/05	Replimune gets third chance at US approval for skin cancer drug
28/05	US FDA advisers vote in favor of recommending COVID vaccines target XFG variant
28/05	Moderna is prepared to supply recommended COVID vaccine composition for 2026-27 season by mid-August: briefing docs
28/05	FDA advisers recommend COVID vaccines be updated to target current dominant variant
26/05	US FDA advisers to weigh updating 2026-27 COVID vaccines for XFG variant